Check-Cap (NASDAQ:CHEK) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued on Monday. The brokerage set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Down 3.1 %

Check-Cap stock opened at $0.76 on Monday. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.45. The stock has a market cap of $4.42 million, a PE ratio of -0.25 and a beta of 0.19. The business’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.16.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.